Greenwich LifeSciences (GLSI)

Executive Summary

Greenwich LifeSciences (GLSI) is a clinical-stage biopharmaceutical company developing GP2, an immunotherapy aimed at preventing breast cancer recurrences in patients who have undergone surgery. The company's sole pipeline candidate, GLSI-100 (GP2 plus GM-CSF), is currently in a Phase 3 trial (NCT05232916) for breast cancer, with an estimated completion date of December 2026. The study is actively recruiting patients and evaluates recurrence-free survival compared to placebo. While GP2 has shown promise in earlier trials, the company remains heavily reliant on the success of this single asset. With no approved products and limited financial data, Greenwich LifeSciences represents a high-risk, high-reward investment opportunity. The Phase 3 data readout is the primary near-term value driver, but the lack of pipeline diversity and early-stage status contribute to significant uncertainty. The company's valuation is estimated at approximately $329 million, reflecting potential upside if the trial succeeds.

Upcoming Catalysts (preview)

• Q1 2027Phase 3 Topline Data (Placebo + GLSI-100)30% success
• Q3 2026Interim Analysis or DSMB Update20% success
• Q2 2026Regulatory Guidance or FDA Meeting Announcement15% success